Abstract: PO2403
Combined Impact of Presensitization and Delayed Graft Function on Allograft Outcome in Deceased Donor Kidney Transplantation: Nationwide Cohort Study
Session Information
- Clinical and Immunologic Predictors of Post-Transplant Outcomes
October 22, 2020 | Location: On-Demand
Abstract Time: 10:00 AM - 12:00 PM
Category: Transplantation
- 1902 Transplantation: Clinical
Authors
- Chung, Byung ha, Seoul Saint Mary's Hospital, Seocho-gu, Seoul, Korea (the Republic of)
- Lee, Hanbi, Seoul Saint Mary's Hospital, Seocho-gu, Seoul, Korea (the Republic of)
- Park, Yohan, Seoul Saint Mary's Hospital, Seocho-gu, Seoul, Korea (the Republic of)
- Ban, Tae Hyun, Eunpyeong St. Mary’s hospital, Seoul, Korea (the Republic of)
- Song, Sang Heon, Pusan National University Hospital, Busan, Korea (the Republic of)
- Yang, Jaeseok, Seoul National University College of Medicine Department of Internal Medicine, Seoul, Seoul, Korea (the Republic of)
- Ahn, Curie, Seoul National University College of Medicine Department of Internal Medicine, Seoul, Seoul, Korea (the Republic of)
- Yang, Chul Woo, Seoul Saint Mary's Hospital, Seocho-gu, Seoul, Korea (the Republic of)
Group or Team Name
- Korean Organ Transplantation Registry Study group
Background
Pre-sensitization to HLA has detrimental effect on allograft rejection, worse allograft function and survival. Delayed graft function (DGF) is associated with poor allograft outcome by ischemia-reperfusion injury. We undertook analysis to determine combined association of pre-sensitization to HLA and DGF on allograft outcome in deceased donor kidney transplantation (DDKT) and whether there is a synergistic effect.
Methods
In our prospective cohort study, between May 2014 and June 2019, 1370 deceased donor kidney transplants were assigned into 2 groups; pre-sensitized and non-pre-sensitized. Each group was divided into 2 subgroups according to DGF. Pre-sensitization was defined as the presence of donor specific antibodies (DSA) or the presence of panel-reactive antibody (PRA), combination with crossmatch positive. DGF was defined as the need for dialysis before discharge. We compared the clinical outcomes including allograft rejection, the change of allograft function, infectious and cardiovascular complication and allograft survival.
Results
Pre-sensitization group were 137 (10.0%) patients and others (n=1233, 90.0%) belonged to non-sensitized group. Pre-sensitization-DGF subgroup was 21 (15.3%) and pre-sensitization-non-DGF group was 116 (84.7%). Non-pre-sensitization-DGF subgroup was 133 (9.7%) and non-pre-sensitization-non-DGF group was 1100 (80.3%). In both pre-sensitization and non-pre-sensitization groups, allograft function using eGFR by CKD-EPI equation (mL/min/1.73m2) was lower in DGF subgroup than non-DGF subgroup. In contrast, allograft rejection rate showed no significant difference between DGF and non-DGF subgroup within non-pre-sensitization group (15.0% vs 12.9%, p=0.493). There was no significant difference between DGF and non-DGF subgroups in both groups in regard to allograft survival and patient survival.
Conclusion
DGF combined with pre-sensitization had much worse effect on allograft outcome in terms of allograft rejection. Therefore, we suggest more careful monitoring or surveillance for allograft rejection when DGF occurred in DDKT with pre-sensitization to HLA.